← SynDRA
INAVOLISIB
SynDRA canonical compound SYN0040102 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | PIK3CA |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
All known targets
- PIK3CA
- PIK3CG
- PIK3CB
- PIK3CD
Mechanisms of action (all sources)
- PIK3CA INHIBITOR
- PI3-kinase p110-alpha subunit inhibitor
- PIK3CB INHIBITOR
- PIK3CD INHIBITOR
- PIK3CG INHIBITOR
- PI3K inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PIK3CB
- PIK3CD
- PIK3R2
- CACNA1C
- CYP1A2
- CYP2C19
- CYP2C8
- CYP2C9
- CYP2D6
- CYP3A4
- KCNH2
- SCN5A
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Antineoplastic Agents
- Phosphoinositide-3 Kinase Inhibitors
Cross-references
Synonyms
- ITOVEBI
- Itovebi
- GDC-0077
- GDC0077
- RG-6114
- RG6114
- RO-7113755
- RO7113755
- SGEUNORSOZVTOL-CABZTGNLSA-N
- UNII-L4C1UY2NYH
- L4C1UY2NYH
- GTPL9636
- SCHEMBL18360780
- EX-A2685
- ZINC669678973
- Ro7113755
- CS-6459
- HY-101562
- RG 6114
- RO 7113755
- GDC 0077
- RefChem:148062
- PI3K Inhibitor GDC0077
- MFCD31382124
- Inavolisib [USAN]
- X3N
- Itovebi (TN)
- INAVOLISIB [INN]
- Inavolisib (USAN/INN)
- INAVOLISIB [WHO-DD]
- orb1308276
- SCHEMBL29695471
- BDBM295665
- GLXC-24203
- GDC-0077?
- NSC800729
- s8668
- US10112932, Compound 101
- WHO 11204
Look up INAVOLISIB in the interactive SynDRA portal →